Stati Uniti - Ingliż - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) antigen (propiolactone inactivated) (unii: 6f59dl4eet) (influenza a virus a/victoria/2570/2019 ivr-215 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:qwb7m7p3k9), influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) antigen (propiolactone inactivated) (unii: y9cjf75rbv) (influenza a virus a/cambodia/e0826360/2020 ivr-224 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:lw2jc76p6m), influenza b virus b/victoria/705/2 - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11] ) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated

Stati Uniti - Ingliż - NLM (National Library of Medicine)

seqirus pty ltd. - influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) antigen (propiolactone inactivated) (unii: uph9lrj9hu) (influenza a virus a/victoria/4897/2022 ivr-238 (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:x5dyv3mm4n), influenza a virus a/darwin/6/2021 ivr-227 (h3n2) antigen (propiolactone inactivated) (unii: n4uxa9h8ka) (influenza a virus a/darwin/6/2021 ivr-227 (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:zn6bmn7fsq), influenza b virus b/austria/1359417/2021 bvr-26 anti - afluria® quadrivalent is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza a subtype viruses and type b viruses contained in the vaccine. afluria quadrivalent is approved for use in persons 6 months of age and older. afluria quadrivalent is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine (see description [11]) . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to afluria quadrivalent during pregnancy. women who are vaccinated with afluria quadrivalent during pregnancy are encouraged to enroll in the registry by calling 1-855-358-8966 or sending an email to seqirus at us.medicalinformation@seqirus.com . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated b

Kanada - Ingliż - Health Canada

pfizer canada ulc - meningococcal polysaccharide antigen group a; meningococcal polysaccharide antigen group c; meningococcal polysaccharide antigen group w-135; meningococcal polysaccharide antigen group y; tetanus toxoid - kit - 5mcg; 5mcg; 5mcg; 5mcg; 44mcg - meningococcal polysaccharide antigen group a 5mcg; meningococcal polysaccharide antigen group c 5mcg; meningococcal polysaccharide antigen group w-135 5mcg; meningococcal polysaccharide antigen group y 5mcg; tetanus toxoid 44mcg - vaccines

Kanada - Ingliż - Health Canada

sanofi pasteur limited - recombinant haemagglutinin protein-strain a (h1n1); recombinant haemagglutinin protein-strain a (h3n2); recombinant haemagglutinin protein-strain b (victoria); recombinant haemagglutinin protein-strain b (yamagata) - solution - 45mcg; 45mcg; 45mcg; 45mcg - recombinant haemagglutinin protein-strain a (h1n1) 45mcg; recombinant haemagglutinin protein-strain a (h3n2) 45mcg; recombinant haemagglutinin protein-strain b (victoria) 45mcg; recombinant haemagglutinin protein-strain b (yamagata) 45mcg - vaccines